Open AccessComplete withdrawal of glucocorticoids after dupilumab therapy in allergic bronchopulmonary aspergillosis: A case report
Author(s) -
Tadashi Nishimura,
Tadaharu Okano,
Makoto Naito,
Chikashi Tsuji,
Soichi Iwanaka,
Yasumasa Sakakura,
Taro Yasuma,
Hajime Fujimoto,
Cori. D’Alessandro-Gabazza,
Yasuhiro Oomoto,
Tetsu Kobayashi,
Esteban C. Gabazza,
Hidenori Ibata
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i23.6922
Subject(s) - medicine , allergic bronchopulmonary aspergillosis , dupilumab , aspergillosis , dermatology , immunology , asthma , antibody , immunoglobulin e
Allergic bronchopulmonary aspergillosis (ABPA) is an allergic reaction to Aspergillus species that aggravates bronchial asthma. Previous studies demonstrated the glucocorticoid-sparing effect of dupilumab in patients with ABPA. There is no report of complete withdrawal of glucocorticoids after dupilumab.